SQUIRE PATTON BOGGS for RANBAXY INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Implementation of P.L. 111-152, Health Care & Education Reconciliation; H.R. 4, Comprehensive 1099 Taxpayer Protection and Repaymentof Exchange Subsidy Overpayments Act; S. 23, the America Invents Act; H.R. 1, Full Year Continuing Appropriations Act.
Foreign entity interest: Ranbaxy Labs Limited - Interests are same as Registrant.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN JONAS | — |
| ERIC RASMUSSEN | SenCrapoLA04-07andDepPresSec03-02LegIntenHatch2000 |
| MATTHEW TODD TUTEN | RepMichaelBilirakis91-92;93-95;98-01 |
| ANURAG VARMA | — |
Pharmacy PHA
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Implementation of P.L. 111-152, Health Care & Education Reconciliation; H.R. 4, Comprehensive 1099 Taxpayer Protection and Repaymentof Exchange Subsidy Overpayments Act; S. 23, the America Invents Act; H.R. 1, Full Year Continuing Appropriations Act.
Foreign entity interest: Ranbaxy Labs Limited - Interests are same as Registrant.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN JONAS | — |
| ERIC RASMUSSEN | SenCrapoLA04-07andDepPresSec03-02LegIntenHatch2000 |
| MATTHEW TODD TUTEN | RepMichaelBilirakis91-92;93-95;98-01 |
| ANURAG VARMA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.